Royal Bank Of Canada Has Lowered Expectations for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price

Mirum Pharmaceuticals (NASDAQ:MIRM) had its target price lowered by equities researchers at Royal Bank Of Canada from $130.00 to $128.00 in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective suggests a potential upside of 36.23% from the company’s previous close.

MIRM has been the subject of several other research reports. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. Morgan Stanley raised their target price on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a report on Friday, January 30th. Citizens Jmp decreased their price target on shares of Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating on the stock in a research note on Thursday. Leerink Partners set a $100.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, December 10th. Finally, Evercore restated an “outperform” rating and issued a $101.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $111.58.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM traded down $14.66 during mid-day trading on Thursday, hitting $93.96. 733,883 shares of the company traded hands, compared to its average volume of 755,419. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The stock’s fifty day moving average price is $92.67 and its 200-day moving average price is $78.81. The firm has a market cap of $4.83 billion, a price-to-earnings ratio of -109.55 and a beta of 0.49. Mirum Pharmaceuticals has a one year low of $36.88 and a one year high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm had revenue of $148.93 million during the quarter, compared to the consensus estimate of $141.78 million. During the same period in the prior year, the company posted $1.00 EPS. The company’s quarterly revenue was up 49.8% on a year-over-year basis. Research analysts anticipate that Mirum Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 9,108 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $940,856.40. Following the transaction, the chief executive officer directly owned 160,294 shares in the company, valued at $16,558,370.20. This trade represents a 5.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Eric Bjerkholt sold 1,053 shares of Mirum Pharmaceuticals stock in a transaction on Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $101,288.07. Following the sale, the chief financial officer directly owned 43,741 shares of the company’s stock, valued at approximately $4,207,446.79. This trade represents a 2.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 45,136 shares of company stock worth $4,352,029 over the last 90 days. Corporate insiders own 14.36% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC grew its stake in Mirum Pharmaceuticals by 21.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after buying an additional 1,067,722 shares during the last quarter. State Street Corp boosted its holdings in Mirum Pharmaceuticals by 59.2% in the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after acquiring an additional 797,088 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Mirum Pharmaceuticals by 566.8% during the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after acquiring an additional 672,118 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Mirum Pharmaceuticals by 709.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after acquiring an additional 536,674 shares in the last quarter. Finally, Voloridge Investment Management LLC boosted its stake in Mirum Pharmaceuticals by 2,116.6% in the 3rd quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock worth $28,560,000 after purchasing an additional 371,999 shares in the last quarter.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Revenue beat and strong top-line growth: Q4 revenue was $148.93M vs. consensus $141.78M, up ~49.8% year-over-year — evidence of accelerating commercial traction. Business Wire: Q4 Results
• Neutral Sentiment: Earnings call details available — management provided a business update and commentary on execution and the outlook; read the call transcript for color on commercial drivers and any pipeline or margin comments. Fool: Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Market momentum and technicals are under discussion — sentiment pieces note strong upward momentum over the past year but warn technical indicators are stretched, which could amplify near-term volatility. Seeking Alpha: Technicals Article
• Negative Sentiment: EPS miss and ongoing GAAP loss: Q4 EPS of ($0.11) missed consensus $0.02, and the company remains unprofitable (negative net margin and ROE), which keeps profitability risk front-and-center for investors. Zacks: Q4 Loss, Revenue Beat
• Negative Sentiment: FY2026 revenue guidance of $630M–$650M is slightly below consensus (~$645.9M) and EPS guidance was not clearly raised in the release, leaving uncertainty on near-term profitability improvement. Business Wire: Guidance

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.